Investor Relations

2017 News Releases

Webcast ImageWebcast
KemPharm Inc at the RBC Capital Markets 2017 Global Healthcare  (Replay)
02/22/17 at 9:00 a.m. ET
KemPharm Inc at the RBC Capital Markets 2017 Global Healthcare
Wednesday, February 22, 2017 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/23/17KemPharm Announces Additional Patent Protection for Prodrug Portfolio
US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family CORALVILLE, Iowa, Feb. 23, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced enhancements to its U.S. and global intellectual property estate governing its portfolio of prodrug product candidates.  The United States Patent and Trademark Offic... 
Printer Friendly Version
02/07/17KemPharm to Present at Upcoming Investor Conferences
Management Presentations to Focus on Depth of Product Pipeline CORALVILLE, Iowa, Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following five investor conferences during February and March. Details of KemPharm's presentations are as follows: Even... 
Printer Friendly Version
01/09/17KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain
Statistically significant pharmacokinetic and pharmacodynamic differences of abuse potential were observed in the KP511.A01 Study CORALVILLE, Iowa, Jan. 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the results of its exploratory Phase 1, double-blind, single-dose, 2-treatment, 2-period, randomized, crossover study (Study KP511.A01) intended to ass... 
Printer Friendly Version
01/04/17KemPharm to Present at Biotech Showcase 2017
CORALVILLE, Iowa, Jan. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle, Ph.D., will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square. Details of KemPharm's presentation are as follows: Event:   Biotech Showcase 20... 
Printer Friendly Version